| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| A Shimatsu, H Murabe, Y Nakamura, T Usu. Rebound hypersecretion of GH following octreotide withdrawal due to liver dysfunction in an acromegalic patient. Endocrine journal. vol 47. issue 5. 2001-03-01. PMID:11200946. |
we report a patient with acromegaly who showed rebound elevation of gh and insulin-like growth factor-1 (igf-1) after octreotide withdrawal. |
2001-03-01 |
2023-08-12 |
Not clear |
| W M Lee, M Diaz-Espineira, J A Mol, A Rijnberk, H S Kooistr. Primary hypothyroidism in dogs is associated with elevated GH release. The Journal of endocrinology. vol 168. issue 1. 2001-02-22. PMID:11139770. |
this elevated gh secretion has endocrine significance as illustrated by elevated plasma igf-i levels and some physical changes mimicking acromegaly. |
2001-02-22 |
2023-08-12 |
Not clear |
| C Parkinson, P J Traine. Pegvisomant: a growth hormone receptor antagonist for the treatment of acromegaly. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 10 Suppl B. 2001-02-01. PMID:10984267. |
initial studies suggest that pegvisomant is a highly effective antagonist of gh action in patients with acromegaly. |
2001-02-01 |
2023-08-12 |
Not clear |
| C Parkinson, P J Traine. Pegvisomant: a growth hormone receptor antagonist for the treatment of acromegaly. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 10 Suppl B. 2001-02-01. PMID:10984267. |
the blockade of gh action, rather than the inhibition of pituitary gh secretion, represents a novel concept in the medical management of acromegaly. |
2001-02-01 |
2023-08-12 |
Not clear |
| C Camacho-Hübne. Assessment of growth hormone status in acromegaly: what biochemical markers to measure and how? Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 10 Suppl B. 2001-02-01. PMID:10984268. |
various studies have evaluated the usefulness of measuring insulin-like growth factor i (igf-i) and igf-binding proteins, compared with growth hormone (gh), in the diagnosis and follow-up of patients with acromegaly. |
2001-02-01 |
2023-08-12 |
Not clear |
| C Camacho-Hübne. Assessment of growth hormone status in acromegaly: what biochemical markers to measure and how? Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 10 Suppl B. 2001-02-01. PMID:10984268. |
the highly sensitive gh assays are now being used in the diagnosis of patients with acromegaly and in post-treatment follow-up. |
2001-02-01 |
2023-08-12 |
Not clear |
| T Kikuchi, S Yabe, T Kanda, I Kobayash. Antipituitary antibodies as pathogenetic factors in patients with pituitary disorders. Endocrine journal. vol 47. issue 4. 2000-12-22. PMID:11075721. |
apa levels detected by elisa were significantly higher in patients with gh deficiency, isolated acth deficiency, acromegaly, and idiopathic panhypopituitarism compared with control (mean +/- sd; 2.40+/-2.66, 2.36+/-1.87, 2.09+/-1.87, 3.10+/-1.96 versus 1.42+/-0.64 (c.i.) |
2000-12-22 |
2023-08-12 |
rat |
| H Naritaka, T Kameya, Y Sato, S Furuhata, M Otani, T Kawas. Morphological characterization and subtyping of silent somatotroph adenomas. Pituitary. vol 1. issue 3-4. 2000-12-19. PMID:11081203. |
the reported cases are characterized by normal or slightly elevated serum levels of gh but without acromegaly. |
2000-12-19 |
2023-08-12 |
Not clear |
| I M Holdaway, C Rajasoory. Epidemiology of acromegaly. Pituitary. vol 2. issue 1. 2000-12-07. PMID:11081170. |
acromegaly is a consequence of chronic growth hormone (gh) excess, due in the majority of cases to a gh-secreting pituitary adenoma, and occurring with a population prevalence of 60 per million and an incidence of 3-4 per million per year. |
2000-12-07 |
2023-08-12 |
Not clear |
| I M Holdaway, C Rajasoory. Epidemiology of acromegaly. Pituitary. vol 2. issue 1. 2000-12-07. PMID:11081170. |
such 'curative' levels of gh are achieved in only about 50% of patients with current therapies, and as a result there is an ongoing excess of patients with chronic complications of acromegaly leading to increased morbidity and mortality from the disorder, with observed-to-expected mortality ratios ranging from 1.6-3.3 and only approaching unity in those with growth hormone levels < 2.5 ug/l following treatment. |
2000-12-07 |
2023-08-12 |
Not clear |
| M R Drange, S Melme. Molecular pathogenesis of acromegaly. Pituitary. vol 2. issue 1. 2000-12-07. PMID:11081171. |
acromegaly is generally caused by growth hormone (gh) hypersecretion from a benign, monoclonal pituitary adenoma. |
2000-12-07 |
2023-08-12 |
Not clear |
| S R Peacey, S M Shale. Growth hormone pulsatility in acromegaly following radiotherapy. Pituitary. vol 2. issue 1. 2000-12-07. PMID:11081174. |
radiotherapy continues to have an important role in the treatment of acromegaly and is particularly effective at halting tumour growth, causing tumour shrinkage and reducing growth hormone (gh) concentrations in the long term. |
2000-12-07 |
2023-08-12 |
Not clear |
| S R Peacey, S M Shale. Growth hormone pulsatility in acromegaly following radiotherapy. Pituitary. vol 2. issue 1. 2000-12-07. PMID:11081174. |
the 24 hour gh profile in active acromegaly compared with normals, characteristically shows an increased frequency of gh pulses, increased disorderliness (approximate entropy) of gh release, increased mean gh valley nadir, increased non-pulsatile fraction of gh and either similar or increased gh pulse amplitude. |
2000-12-07 |
2023-08-12 |
Not clear |
| S R Peacey, S M Shale. Growth hormone pulsatility in acromegaly following radiotherapy. Pituitary. vol 2. issue 1. 2000-12-07. PMID:11081174. |
however, very few data are available regarding the effects of radiotherapy on gh pulsatility in patients with acromegaly. |
2000-12-07 |
2023-08-12 |
Not clear |
| J A Mol, I Lantinga-van Leeuwen, E van Garderen, A Rijnber. Progestin-induced mammary growth hormone (GH) production. Advances in experimental medicine and biology. vol 480. 2000-12-01. PMID:10959411. |
toxicity studies using beagle dogs revealed in the 1980s that synthetic progestins may induce a syndrome of growth hormone (gh) excess, known as acromegaly, and the development of predominantly benign mammary hyperplasia. |
2000-12-01 |
2023-08-12 |
dog |
| W H Daughada. Growth hormone axis overview--somatomedin hypothesis. Pediatric nephrology (Berlin, Germany). vol 14. issue 7. 2000-11-30. PMID:10912514. |
measurement of serum igf-i is the most-valuable index of gh hypersecretion in acromegaly and in conditions of growth impairment. |
2000-11-30 |
2023-08-12 |
rat |
| I Shimon, D Nass, M Hadan. Acromegaly with normal growth hormone levels: response to Sandostatin-LAR treatment. Pituitary. vol 2. issue 4. 2000-11-30. PMID:11081151. |
we report a case of acromegaly with relatively low gh secretion in a patient with gh-secreting pituitary macroadenoma. |
2000-11-30 |
2023-08-12 |
Not clear |
| I Shimon, D Nass, M Hadan. Acromegaly with normal growth hormone levels: response to Sandostatin-LAR treatment. Pituitary. vol 2. issue 4. 2000-11-30. PMID:11081151. |
this is a rare case of acromegaly without elevated gh levels, and good response to treatment with somatostatin analog, as expected in classical gh-secreting pituitary adenomas. |
2000-11-30 |
2023-08-12 |
Not clear |
| F Manelli, P Desenzani, E Boni, G Bugari, F Negrini, G Romanelli, V Grassi, A Giustin. Cardiovascular effects of a single slow release lanreotide injection in patients with acromegaly and left ventricular hypertrophy. Pituitary. vol 2. issue 3. 2000-11-30. PMID:11081155. |
in conclusion, these results suggest that in acromegalic patients: (1) sr-l causes a rapid improvement in baseline cardiac function and in cardiopulmonary performance during exercise in acromegaly; (2) the endocrine (decrease in gh levels) and echocardiographic responses to sr-l are maximal after 7 days from the injection, whereas the effect of sr-l on the exercise performance are longer lasting. |
2000-11-30 |
2023-08-12 |
Not clear |
| Y C Patel, S Ezzat, C L Chik, O P Rorstad, O Serri, E Ur, G E Wilkin. Guidelines for the diagnosis and treatment of acromegaly: a Canadian perspective. Clinical and investigative medicine. Medecine clinique et experimentale. vol 23. issue 3. 2000-11-20. PMID:10911548. |
acromegaly is a chronic, debilitating condition caused by excessive secretion of growth hormone (gh). |
2000-11-20 |
2023-08-12 |
Not clear |